NR4A1 and cancer: Finally, the lower access of women with SMI to the most intensive combination of cancer treatment could be explained by clinical factors which were not measurable in our research, such as grading, hormonal receptor status (but we matched cases and controls on age that strongly drives this status), biomarkers, or histological subtypes which are important for some treatment choices [66].